Cite
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
MLA
Ramonda, Roberta, et al. “Four-Year Effectiveness, Safety and Drug Retention Rate of Secukinumab in Psoriatic Arthritis: A Real-Life Italian Multicenter Cohort.” Arthritis Research & Therapy, vol. 26, no. 1, Sept. 2024, p. 172. EBSCOhost, https://doi.org/10.1186/s13075-024-03401-x.
APA
Ramonda, R., Lorenzin, M., Chimenti, M. S., Atzeni, F., Semeraro, A., D’Angelo, S., Selmi, C., Ortolan, A., Marchesoni, A., Manara, M., Luchetti Gentiloni, M. M., Santo, L., Salvarani, C., Cauli, A., Rossini, M., Amato, G., Cozzi, G., Scagnellato, L., Ferraioli, M., … Carletto, A. (2024). Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis Research & Therapy, 26(1), 172. https://doi.org/10.1186/s13075-024-03401-x
Chicago
Ramonda, Roberta, Mariagrazia Lorenzin, Maria Sole Chimenti, Fabiola Atzeni, Angelo Semeraro, Salvatore D’Angelo, Carlo Selmi, et al. 2024. “Four-Year Effectiveness, Safety and Drug Retention Rate of Secukinumab in Psoriatic Arthritis: A Real-Life Italian Multicenter Cohort.” Arthritis Research & Therapy 26 (1): 172. doi:10.1186/s13075-024-03401-x.